Alpelisib works by inhibiting the PI3K enzyme, specifically the alpha isoform (PI3K-alpha). This inhibition disrupts the PI3K/AKT/mTOR signaling pathway, which is frequently activated in various cancers. By blocking this pathway, Alpelisib helps to reduce cancer cell proliferation and induces apoptosis, or programmed cell death, in cancer cells.
